Literature DB >> 8024359

Prostaglandin E1 increases survival with extended anhepatic phase during liver transplantation.

H S Xu1, L K Rosenlof, T L Pruett, R S Jones.   

Abstract

OBJECTIVE: The authors investigated the intraoperative treatment effects of Prostaglandin E1 (PGE1) for extension of the anhepatic phase and improvement of survival in a rat liver transplant model.
BACKGROUND: Cross-clamping the inferior vena cava and the portal vein during liver transplantation causes severe pathophysiologic changes during surgery. The time of the anhepatic phase is strictly limited and results in a very tenuous period during the liver transplant operation.
METHODS: Prostaglandin E1 was infused at 0.5 microgram/kg/min into five subgroups of rats with 20, 30, 40, 60, and 80 minutes of anhepatic phase during transplantation. Bile secretion, serum aspartate transaminase (AST), lactic dehydrogenase (LDH), and blood gas analysis were studied in the 30-minute subgroup. The results were compared with the sham-operated and control groups.
RESULTS: Intraoperative treatment with PGE1 extended the maximal anhepatic phase from 30 minutes in the sham-operated group up to 80 minutes, and increased survival. Significant changes in the PGE1 treated rats in the 30-minute subgroup included an increase of bile flow and bile salt output and decrease of AST and LDH activities after surgery. Blood gas analysis showed a decrease in acidosis and hypercarbia at the end of the anhepatic phase.
CONCLUSIONS: The PGE1 treatment increased survival with extended anhepatic phase during rat liver transplantation. The beneficial effects can be attributed to its biologic activities.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8024359      PMCID: PMC1234287          DOI: 10.1097/00000658-199407000-00009

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  30 in total

1.  Mechanics of bile secretion; effect of perfusion pressure and temperature on bile flow and bile secretion pressure.

Authors:  R W BRAUER; G F LEONG; R J HOLLOWAY
Journal:  Am J Physiol       Date:  1954-04

2.  Is there a post-reperfusion syndrome?

Authors:  S Aggarwal; Y Kang; J Freeman; A M DeWolf; B Begliomini
Journal:  Transplant Proc       Date:  1989-06       Impact factor: 1.066

Review 3.  Preservation and reperfusion injuries in liver allografts. An overview and synthesis of current studies.

Authors:  P A Clavien; P R Harvey; S M Strasberg
Journal:  Transplantation       Date:  1992-05       Impact factor: 4.939

4.  Renal hemodynamics, urinary eicosanoids, and endothelin after liver transplantation.

Authors:  S C Textor; D J Wilson; A Lerman; J C Romero; J C Burnett; R Wiesner; E R Dickson; R A Krom
Journal:  Transplantation       Date:  1992-07       Impact factor: 4.939

5.  Preservation of the canine liver for 24-48 hours using simple cold storage with UW solution.

Authors:  N V Jamieson; R Sundberg; S Lindell; K Claesson; J Moen; P K Vreugdenhil; D G Wight; J H Southard; F O Belzer
Journal:  Transplantation       Date:  1988-10       Impact factor: 4.939

6.  The beneficial effect of a prostaglandin I2 analog on ischemic rat liver.

Authors:  S Suzuki; S Nakamura; T Koizumi; S Sakaguchi; S Baba; H Muro; Y Fujise
Journal:  Transplantation       Date:  1991-12       Impact factor: 4.939

7.  Liver transplantation in children.

Authors:  R W Busuttil; P Seu; J M Millis; K M Olthoff; J R Hiatt; A Milewicz; B Nuesse; G el-Khoury; D Raybould; A Nyerges
Journal:  Ann Surg       Date:  1991-01       Impact factor: 12.969

8.  Hepatic microcirculatory disturbances due to portal vein clamping in the orthotopic rat liver transplantation model.

Authors:  I Marzi; J Knee; M D Menger; G Harbauer; V Bühren
Journal:  Transplantation       Date:  1991-09       Impact factor: 4.939

9.  A surgical experience with five hundred thirty liver transplants in the rat.

Authors:  N Kamada; R Y Calne
Journal:  Surgery       Date:  1983-01       Impact factor: 3.982

10.  Improved survival after orthotopic liver grafting.

Authors:  R Y Calne; R Williams; M Lindop; J V Farman; M E Tolley; K Rolles; B MacDougall; J Neuberger; R J Wyke; A T Raftery; T J Duffy; D G Wight; D J White
Journal:  Br Med J (Clin Res Ed)       Date:  1981-07-11
View more
  4 in total

1.  Prostaglandin E1 treatment.

Authors:  C Yegen; A O Aktan; S Yalcin; R Yalin
Journal:  Ann Surg       Date:  1995-12       Impact factor: 12.969

2.  The mechanism of hepatic graft protection against reperfusion injury by prostaglandin E1.

Authors:  H Itasaka; T Suehiro; S Wakiyama; K Yanaga; M Shimada; K Sugimachi
Journal:  Surg Today       Date:  1999       Impact factor: 2.549

Review 3.  Lipids in Liver Failure Syndromes: A Focus on Eicosanoids, Specialized Pro-Resolving Lipid Mediators and Lysophospholipids.

Authors:  Florent Artru; Mark J W McPhail; Evangelos Triantafyllou; Francesca Maria Trovato
Journal:  Front Immunol       Date:  2022-03-31       Impact factor: 7.561

Review 4.  A systematic review of pharmacological treatment options used to reduce ischemia reperfusion injury in rat liver transplantation.

Authors:  Kenya Yamanaka; Philipp Houben; Helge Bruns; Daniel Schultze; Etsuro Hatano; Peter Schemmer
Journal:  PLoS One       Date:  2015-04-28       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.